^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

ADXS-PSA

i
Other names: ADXS-PSA, ADXS31-142, live attenuated Listeria-based prostate cancer vaccine, Lovaxin P, ADXS PSA, ADXS 31142, ADXS-31142
Associations
Trials
Company:
Ayala Pharma
Drug class:
KLKB1 inhibitor
Associations
Trials
9ms
Trial completion • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • ADXS-PSA
almost5years
KEYNOTE-046 (Part B): Effects of ADXS-PSA in combination with pembrolizumab on survival in metastatic, castration-resistant prostate cancer patients with or without prior exposure to docetaxel. (ASCO-GU 2020)
Results with ADXS-PSA in combination with pembrolizumab in mCRPC, with or without prior docetaxel, show promising clinical activity to be further assessed in randomized studies. Clinical trial information: NCT02325557. Research Funding: None.
Clinical • Combination therapy
|
KLK3 (Kallikrein-related peptidase 3)
|
Keytruda (pembrolizumab) • docetaxel • ADXS-PSA
almost5years
KEYNOTE-046 (Part B): Effects of ADXS-PSA in combination with pembrolizumab on survival in metastatic, castration-resistant prostate cancer patients with or without prior exposure to docetaxel. (ASCO-GU 2020)
Results with ADXS-PSA in combination with pembrolizumab in mCRPC, with or without prior docetaxel, show promising clinical activity to be further assessed in randomized studies. Clinical trial information: NCT02325557. Research Funding: None.
Clinical • Combination therapy
|
KLK3 (Kallikrein-related peptidase 3)
|
Keytruda (pembrolizumab) • docetaxel • ADXS-PSA